Compare Centene Corp (CNC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs GeneDx Holdings Corp — how do they compare? Centene Corp trades at $66.6 (market cap $32.05B), while GeneDx Holdings Corp trades at $82.4 (market cap $2.44B). The key difference: Centene Corp is far larger — about 13.1× GeneDx Holdings Corp's market cap, and Centene Corp is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| CNC | WGS | |
|---|---|---|
Market Cap | $32.05B | $2.44B |
Sector | Health | Technology |
52-Week High | $68.72 | $167.51 |
52-Week Low | $26.17 | $34.51 |
Enterprise Value | $21.10B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $66.94, up 0.57% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates with EPS of $2.51 versus $1.09 expected, driven by margin recovery and cost control. The stock shows attractive valuation metrics, including a P/E of 8.06 and P/S of 0.16, while revenue growth remains robust at $194.78B in 2025.
Outlook is positive with a consensus price target of $71.00, though risks include Medicaid membership volatility and net income margin pressure. The company's raised 2026 EPS guidance and operational cash flow strength support upside potential, but investors should weigh competitive and regulatory challenges in the managed care sector.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
